Search Results

disease, and (3) adjuvant therapy with modified FOLFIRINOX (leucovorin/5-FU/irinotecan/oxaliplatin) for patients who are able to tolerate it. Presenting these updates was Margaret A. Tempero, MD, Professor of Medicine, and Director of the UCSF Pancreas

regimen is mFOLFIRINOX (oxaliplatin 85 mg/m 2 , leucovorin 400 mg/m 2 , irinotecan 150 mg/m 2 , and 5-FU infusion 2.4 g/m 2 over 46 hours, without bolus, given every 2 weeks for 12 cycles). 5 This regimen was compared with single-agent gemcitabine 1000

cohort, we selected patients who received a standard first-line chemotherapy doublet defined as 5-FU/oxaliplatin (FOLFOX), capecitabine/oxaliplatin (CAPEOX), or 5-FU/irinotecan (FOLFIRI). Within this group, only patients who were documented as having RAS

: Fluoropyrimidine, platinum, and irinotecan (eg, FOLFIRINOX [5-FU/leucovorin/oxaliplatin/irinotecan]) Regimens with gemcitabine and nab-paclitaxel Gemcitabine monotherapy Other regimens Predictor Preselection Predictors were selected based on

myelosuppressive agent. Error bars indicate 95% CI. Abbreviations: 5-FU, 5-fluorouracil; ABVD, doxorubicin, bleomycin, vinblastine, dacarbazine; AC, doxorubicin, cyclophosphamide; CRC, colorectal cancer; FOLFOX4/mFOLFOX6, folinic acid, 5-fluorouracil, oxaliplatin

, patients with metastatic pancreatic cancer were randomly assigned to receive gemcitabine or a combination chemotherapy regimen consisting of oxaliplatin/irinotecan/fluorouracil/leucovorin (FOLFIRINOX). 4 To be enrolled, patients were required to have an

IDEA trial has provided results that will be very helpful for clinicians. 2 IDEA was a combined analysis of 6 individual studies that determined whether 3 months of adjuvant oxaliplatin-based therapy was as effective as, and less neurotoxic than, 6

Kang WK Kwon JM . Phase II trial of irinotecan plus oxaliplatin and 5-fluorouracil/leucovorin in patients with untreated metastatic gastric adenocarcinoma . Ann Oncol 2007 ; 18 : 88 – 92 . 20. Bamias A Papamichael D Syrigos K . Phase II

FOLFOX or used capecitabine and oxaliplatin as an induction regimen. We are conducting a phase 2 prospective clinical trial to evaluate the use of 6 cycles of FOLFOX as TNT in patients with T2-T3/N0-N+. Patients and Methods: Patients with T2-T3/N0-N

(95% CI: 12.07, 13.6). The most common 1L regimens were fluoropyrimidine + oxaliplatin (n=651, 22.4%), platinum (ie, cisplatin or carboplatin) + taxane (n=511, 17.5%), and single-agent fluoropyrimidine (n=280, 9.6%). 1,230 patients received second line